Đang chuẩn bị liên kết để tải về tài liệu:
A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

PEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of irinotecan encapsulated in liposomes. The aims of this study were to investigate the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02 in combination with 5-FU and LV, in patients with advanced refractory solid tumors. |

TÀI LIỆU LIÊN QUAN

Health-related quality of life as an endpoint in oncology phase I trials: A systematic review

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: Study protocol

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease smallcell lung cancer (LD-SCLC): TORG 0604

Optimal biological dose: A systematic review in cancer phase I clinical trials

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

A prospective phase I study of hypofractionated neoadjuvant radiotherapy for locally advanced gastric cancer

A web tool for designing and conducting phase I trials using the continual reassessment method

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.